Table 2.
Cellular assays results.
| Compound | Antiviral activity EC50a UC-1074 #1 strain Vero cells |
Antiviral activity EC50a UC-1075 #1 strain Vero cells |
Cytotoxicity |
|
|---|---|---|---|---|
| 15 μl/10 mL | 100 μl/10 mL | Cell morphology (MCC)b | Cell growth (CC50)c | |
| Remdesivir | 0.87 μM | 0.61 μM | >40 μM | >40 μM |
| 7 | >100 μM | >100 μM | >100 μM | >100 μM |
| 22 | 2.19 μM | 2.01 μM | > 100 μM | 1.49 μM |
| 23 | >4 μM | >4 μM | 20 μM | 10.61 μM |
| 24 | >4 μM | >4 μM | 20 μM | 4.67 μM |
| 25 | >4 μM | >20 μM | ≥20 μM | 34.70 μM |
| 26 | 63.14 μM | >20 μM | ≥100 μM | 78.37 μM |
| 27 | 8.94 μM | 10.94 μM | ≥ 100 μM | 51.52 μM |
| 28 | >20 μM | >20 μM | >100 μM | 42.35 μM |
| 29 | 0.32 μM | 1.37 μM | 100 μM | 38.67 μM |
| 34 | 5.98 μM | 0.44 μM | 100 μM | 31.53 μM |
| 35 | 4 μM | 20 μM | 100 μM | 8.09 μM |
a
Effective concentration required to reduce virus plaque formation by 50%. Virus input was 100 CCID50.
b
Minimum cytotoxic concentration that causes a microscopically detectable alteration of cell morphology.
c
Cytotoxic concentration required to reduce cell growth by 50%.